IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, Faslodex 250 mg solution for injection., JZP598
ZWI-ZW25-202
Phase 2 small_molecule active
Quick answer
IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, Faslodex 250 mg solution for injection., JZP598 for Breast cancer patients including those with locally advanced (unresectable) or metastatic HER2-positive, HR-positive breast cancer is a Phase 2 program (small_molecule) at Jazz Pharmaceuticals Ireland Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Jazz Pharmaceuticals Ireland Limited
- Indication
- Breast cancer patients including those with locally advanced (unresectable) or metastatic HER2-positive, HR-positive breast cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active